Last reviewed · How we verify
NCT04543604
Understanding, Modulation and Memorization of Indicators Associated to Peri-implantitis
NA trial testing Leatlet + visual aid (pictogram) in Peri-Implantitis in 99 participants. Completed in 9 June 2021.
9 June 2021
Quick facts
| Lead sponsor | Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 99 |
| Start date | 10 February 2018 |
| Primary completion | 9 June 2021 |
| Estimated completion | 9 June 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Leatlet + visual aid (pictogram)
- Leaflet + no visual aid (no pictogram)
Conditions studied
- Peri-Implantitis — all drugs for Peri-Implantitis →
Sponsor
Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain — full company profile →
Who can join
Adults 18 to 80, any sex, with Peri-Implantitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Communication strategies are encouraged to enhance patients´ understanding of potential events related to implant therapy such as peri-implantitis. Moreover, it is key to provide accurate information to patients receiving dental implants to reduce false expectations and to minimize the alterations concerning satisfaction. Information leaflets based in the "health-belief model" proved efficiency in improving health judgments, decisions and behaviors, in particular when supplemented with visual aids. Hence, it was the purpose of the present study to test the effectiveness of different communication strategies to enhance and modulate the understanding and memorization of risk indicators associated to peri-implantitis. A prospective randomized controlled three-arm study is being conducted in accordance with the Declaration of Helsinki on human studies. Three groups are defined to test the hypothesis that visual aids improve the understanding, modulation and memorization of peri-implantitis and related indicators as follows: * Test group1 - Leaflet with visual aid (L-VA): Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included (supplementary figure 1). Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator. * Test group2 - Leaflet with visual aid (L-NVA): Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included (supplementary figure 2). Relevant scientific bibliography supported the statements. No pictograms were supplemented. * Control group - No leaflet (NL): Only verbal information was provided to the patient during initial interview. Patients will be randomly assigned to the tests or control groups according to the last digit of their chart number. As such, patients with records ending 1-4, 4-7 and 8-0 were included in test group1, test group2 and control group, respectively. When reached the total sample size of any of the groups, patients were only recruited for the remaining groups to complete the total sample size. A questionnaire based on the "health-belief model" will be collected from every eligible patient at baseline, 3- and 6-month follow-up
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comprehension and recall of information about factors associated with peri-implantitis: A randomized controlled trial.
Monje A, Pérez A, Vera-Rodriguez M, Nart J, et al · · 2022 · cited 1× · PMID 33949680 · DOI 10.1002/jper.21-0018
Verify or expand the search:
- PubMed search for NCT04543604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peri-Implantitis
Currently open trials in the same condition.
- NCT07012915 — Immunological-Clinical Evaluation of the Etiopathogenesis of Peri-Implantitis · NA · recruiting
- NCT06679283 — Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) · NA · recruiting
- NCT06017817 — Antibacterial Photodynamic Therapy in the Management of Peri-implantitis · NA · recruiting
- NCT06364982 — Distance Between Dental Implants as a Risk Indicator for Peri-implant Disease. · recruiting
- NCT06288919 — Erythritol vs Ultrasonic Scaler Prophylaxis Systems on Dental Implants With Crowns Made by Different Materials · NA · active not recruiting
Other Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain trials
Trials by the same sponsor.
- NCT06398288 — Adjunctive Use of Dermal Matrix to Compensate Dimensional Changes in the Reconstructive Therapy of Peri-implantitis · NA · recruiting
- NCT05772078 — Compliance and Cumulative Interceptive Rate After Therapy of Peri-implantitis · completed
- NCT06390124 — Reconstructive Therapy of Peri-implantitis with PDGF-BB (Gem-21) · Phase 4 · completed
- NCT05615051 — Influence of Implant Surface Decontamination on the Reconstructive Outcomes of Peri-implantitis · NA · active not recruiting
- NCT04410614 — Dimensional Changes of Free Epithelial Graft at Teeth and Implant Sites · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04543604 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
- Last refreshed: 10 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04543604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing